Published September 20, 2005
| Version v1
Journal article
Open
Immunological Prevention of a Multigene Cancer Syndrome
Authors/Creators
- 1. 1Cancer Research Section, Department of Experimental Pathology and
- 2. 1Cancer Research Section, Department of Experimental Pathology and; 2Istituti Ortopedici Rizzoli, Bologna, Italy;
- 3. 1Cancer Research Section, Department of Experimental Pathology and; 3Interdepartment Center for Cancer Research "Giorgio Prodi," University of Bologna, Bologna, Italy;
- 4. 4Center of Excellence on Aging (CeSI), "G. D'Annunzio" University, Chieti, Italy; and
- 5. 5Department of Clinical and Biological Sciences, University of Turin, Orbassano, Italy
Description
Abstract
Vaccines effectively prevent the onset of tumors in transgenic mice carrying activated oncogenes; however, human tumors are caused by combined alterations in oncogenes and oncosuppressor genes. We evaluated the impact of prophylactic vaccines in HER-2/neu transgenic, p53 wild-type/null mice that succumb to an aggressive cancer syndrome comprising mammary and salivary gland carcinomas and rhabdomyosarcoma. A vaccine made of allogeneic mammary carcinoma cells expressing HER-2/neu and interleukin 12 afforded long-term protection from tumor onset. Tumor prevention was mediated by T cell–derived cytokines, in particular γ-interferon, and by anti–HER-2/neu antibodies. HER-2/neu expression was inhibited in target tissues of vaccinated mice, and somatic loss of the wild-type p53 allele did not occur. A highly effective vaccine against a single oncoprotein induced a powerful immune response that arrested multistep carcinogenesis in distinct target tissues.
Files
fulltext.pdf
Files
(687.1 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:98e85e51ec8988b30751dc2590a9cef0
|
687.1 kB | Preview Download |